45.Issue 07 july 26 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 13, Issue : 07, July – 2026

Title:

EFFECTS OF ORAL CONTRACEPTIVE PILLS IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME

Authors :

A.V. Kishore Babu*, Manthri Vennela, Safiya Basalat, Sana, Shireen fathima, Shaivalini Kamarapu

Abstract :

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, characterised by hyperandrogenism, ovulatory dysfunction, and polycyctic ovarian morphology, oral contraceptive pills(OCPs) are widely used as a first-line pharmacological treatment to manage the symptoms of PCOS,particularly menstrual irregularities, acne, and hirsutism. this review examines the therapeutic effects of combined OCPs, which typically contain estrogen and progestin,in regulating menstrual cycles, suppressing ovarian androgen production,and increasing sex hormone–binding globulin(SHBG) levels,thereby reducing free testosterone levels.While effective in symptom management,OCPs do not address the underlying metabolic dysfunction often associated with PCOS such as insulin resistance and obesity.the choice of OCP formulation and duration of therapy can influence treatment outcomes and side-effect profiles. Lon-term use of OCPs is generally considered safe for most women with PCOS,but individual risk factors must be assessed. Further research is needed to optimize individualized treatment stratergies and evaluate long term outcomes.
Key Words : Polycystic ovary syndrome, hyperandrogenism, sex hormone –binding globulin, oral contraceptive pills & poly cystic ovarian syndrome.

Cite This Article:

Please cite this article in press A.V. Kishore Babu et al., Effects Of Oral Contraceptive Pills In The Treatment Of Polycystic Ovary Syndrome, Indo Am. J. P. Sci, 2026; 13(07).

REFERENCES:

1. Kollmann M, Martins WP, Raine-Fenning N (2014). “Terms and thresholds for the ultrasound evaluation of the ovaries in women with hyperandrogenic anovulation”. Human Reproduction Update. 20 (3): 463–464.
2. Legro RS (2017). “Stein-Leventhal syndrome”. Encyclopedia Britannica. Retrieved 30 January 2021.
3. “What are the symptoms of PCOS?”. Eunice Kennedy Shriver National Institute of Child Health and Human Development.
4. “Polycystic Ovary Syndrome (PCOS): Condition Information”. National Institute of Child Health and Human Development. January 31, 2017. Retrieved 19 November 2018.
5. “Is there a cure for PCOS?”. Eunice Kennedy Shriver National Institute of Child Health and Human Development.
6. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F (July 2016). “Genetic, hormonal and metabolic aspects of PCOS: an update”. Reproductive Biology and Endocrinology (Review). 14 (1): 38.
7. Diamanti-Kandarakis E, Kandarakis H, Legro RS (August 2006). “The role of genes and environment in the etiology of PCOS”. Endocrine. 30 (1): 19–26.
8. “What causes PCOS?”. Eunice Kennedy Shriver National Institute of Child Health and Human Development.
9. “How do health care providers diagnose PCOS?”. Eunice Kennedy Shriver National Institute of Child Health and Human Development.
10. Mortada R, Williams T (August 2015). “Metabolic Syndrome: Polycystic Ovary Syndrome”. FP Essentials (Review). 435:
11. Giallauria F, Palomba S, Vigorito C, Tafuri MG, Colao A, Lombardi G, Orio F (July 2009). “Androgens in polycystic ovary syndrome: the role of exercise and diet”. Seminars in Reproductive Medicine (Review). 27 (4): 306–315.
12. National Institutes of Health (NIH) (2014-07-14). “Treatments to Relieve Symptoms of PCOS”. Archived from the original on 2 April 2015. Retrieved 13 March 2015.
13. Pal L, ed. (2013). “Diagnostic Criteria and Epidemiology of PCOS”. Polycystic Ovary Syndrome Current and Emerging Concepts. Dordrecht: Springer. Archived from the original on 2017-09-10.
14. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E (November 2015). “American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1”. Endocrine Practice. 21 (11): 1291–1300.
15. Dunaif A, Fauser BC (November 2013). “Renaming PCOS–a two-state solution”. The Journal of Clinical Endocrinology and Metabolism. 98 (11): 4325–4328. . Around 20% of European women have polycystic ovaries (the prevalence is even higher in some other populations) but approximately two-thirds of these women do not have PCOS
16. Khan MJ, Ullah A, Basit S. Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. Appl Clin Genet. 2019 Dec 24.
17. Crespo RP, Bachega TA, Mendonça BB, Gomes LG (June 2018). “An update of genetic basis of PCOS pathogenesis”. Archives of Endocrinology and Metabolism. 62 (3): 352– 361.
18. Muscogiuri G, Altieri B, de Angelis C, Palomba S, Pivonello R, Colao A, Orio F (September 2017). “Shedding new light on female fertility: The role of vitamin D”. Reviews in Endocrine & Metabolic Disorders. 18 (3): 273–283.
19. Lentscher JA, Slocum B, Torrealday S (March 2021). “Polycystic Ovarian Syndrome and Fertility”. Clinical Obstetrics and Gynecology. 64 (1): 65–75.
20. Wolf WM, Wattick RA, Kinkade ON, Olfert MD (November 2018). “Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity”. International Journal of Environmental Research and Public Health. 15 (11): 2589.
21. Polycystic Ovarian Syndrome at eMedicine
Teede H, Deeks A, Moran L (June 2010). “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan”. BMC Medicine. 8 (1): 41.
22. Azziz R (March 2006). “Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature”. The Journal of Clinical Endocrinology and Metabolism. 91 (3): 781–785.
23. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (January 2004). “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)”. Human Reproduction. 19 (1): 41–47.
24. Carmina E (February 2004). “Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines”. Minerva Ginecologica. 56 (1): 1–6.